Orforglipron Hemicalcium — Drug Intelligence | 8 EU Trials

Filter these 8 trials by condition, phase, country and more.

Open in Search →

8 Registered trials

3 Recruiting

5 Completed trials

1 Sponsors

10 Countries

Phase III

Phase III: 8

Oversight events:

1 serious breach across 1 trial

View oversight register →

Sponsors using this IMP

Eli Lilly & Co. 8

All trials

8 total

Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease ( ATTAIN-PAD ) Recruiting

2025-523283-21-00 Phase III 4 countries Eli Lilly & Co.
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight (RESTRAIN-SUI) Recruiting

2025-522514-23-00 Phase III 3 countries Eli Lilly & Co.
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee ( ATTAIN-OA PAIN ) Recruiting

2025-522631-34-00 Phase III 2 countries Eli Lilly & Co.
J2A-MC-GZPO: A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes J2… Ended

2025-521098-14-00 Phase III 2 countries Eli Lilly & Co.
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) A Study of Orforglipron (LY3502970) in Adolescent Partici… Ended

2024-514081-40-00 Phase III 2 countries Eli Lilly & Co.
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1) Ended

2022-502839-19-00 Phase III 2 countries Eli Lilly & Co.
A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control W… Ended

2023-507206-13-00 Phase III 2 countries Eli Lilly & Co.
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight and Type 2 Diabetes (ATTAIN-2) Ended

2022-502837-24-00 Phase III 3 countries Eli Lilly & Co.

Showing 1–8 of 8 trials

← All drugs A–Z